Real-time enrollment status for this focal segmental glomerulosclerosis clinical trial
Current Status
Recruiting
Checked: August 29, 2026 at 7:46 AM UTC
| NCT Number | NCT07268638 |
| Recruiting Status | Recruiting |
| Condition | Focal Segmental Glomerulosclerosis |
| Phase | PHASE2 |
| Target Enrollment | 60 participants |
| Active Locations | 25 sites in the US |
| Sponsor | Akebia Therapeutics |
| Last Updated on CT.gov | August 13, 2026 (2 weeks ago) |
As of August 29, 2026: Clinical trial NCT07268638 is currently recruiting participants. This phase2 study for focal segmental glomerulosclerosis is actively seeking new participants at 25 locations across the United States. The study is sponsored by Akebia Therapeutics. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07268638 is actively recruiting participants as of August 29, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 25 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07268638 was last updated 2 weeks ago (August 13, 2026). HelloStudys verifies this status automatically.